Treatment Outcome of Limited Stage Hodgkin's Disease

다국어 초록 (Multilingual Abstract)

Purpose: The 10-year overall survival rate following conventional treatments for patients with limited-stage Hodgkin's disease (HD) exceeds 90%. However, the clinical features and treatment outcome of HD in Korea have not been extensively characterized due to its low incidence. In this study, we attempted to analyze the treatment outcome of different modalities in limited stage HD patients. Materials and Methods: Twenty one Hodgkin's disease patients, referred to the Samsung Medical Center between January 1997 and December 2003, were enrolled in this study. Limited stage Hodgkin's disease was subdivided into low and high risk groups. All evaluable patients received treatment. Results: There were 13 and 8 patients in the low and high risk groups, respectively. Eighteen patients (86%) obtained complete response (CR) and 3 patients (14%) achieved an undetermined complete response (CRu). Fourteen (67%), 4 (19%) and 3 (14%) cases received combination chemotherapy, radiotherapy alone and chemotherapy alone, respectively. Four cases relapsed and 2 obtained a second CR. The 5-year overall and disease- free survival rates were 90 and 72%, respectively, for all patients. The median follow-up duration was 31 months. There was no difference in disease free survival (DFS) between the low and high risk groups. Although 12 cases had neutropenia greater than grade III, none experienced neutropenic fever. Conclusion: The treatment outcome of limited-stage HD was excellent, regardless to the initial treatment modality.

참고문헌 (Reference)

1 "basing the treatment on the evidence" 178-93, 2001

2 "Two cycles ABVD plusextended field radiotherapy is superior to radiotherapy alonein early stage Hodgkin's disease:Results of the GermanHodgkin's Lymphoma Study Group(GHSG)" 100 : 341-, 2002

3 "The radical radiotherapy of regionally localizedHodgkin's disease" 78 : 553-61, 1962

4 "The evolution and summary resultsof the Stanford randomized clinical trials of the managementof Hodgkin's disease:1962-1984" 11 : 5-22, 1985

5 "Staging laparotomy in the managementof Hodgkin's diseaseIs It Still Necessary?" 1 : 41-55, 1996

6 "Second malignancies after treatment forlaparotomy staged IA-IIIB Hodgkin's disease:long-termanalysis of risk factors and outcome" 87 : 3625-32, 1996

7 "Second cancer risk followingHodgkin's disease:a 20-year follow-up study" 12 : 312-25, 1994

8 "Report of a committee convened to discussthe evaluation and staging of patients with Hodgkin's disease:Cotswolds meeting" 7 : 1630-6, 1989

9 "Radiotherapy in Hodgkin'sdisease" 24 : 277-87, 1992

10 "Phase III randomized intergroup trial ofsubtotal lymphoid irradiation versus doxorubicin,vinblastine,and subtotal lymphoid irradiation for stage IA to IIA Hodgkin'sdisease" 19 : 4238-44, 2001

11 "Malignant lymphomain Korea" 12 : 1-20, 1977

12 "MOPP/ABV hybrid and irradiation in unfavorablesupradiaphragmatic clinical stages I-II Hodgkin's disease: Comparisonof three treatment modalities. Preliminary results of theEORTC-GELA H8-U randomized trial in 995 patients" 96 : 576-, 2000

13 "MOPP chemotherapy versus extended- fieldradiotherapy in the management of pathological stages I-IIAHodgkin's disease" 7 : 732-7, 1989

14 "Involved-field radiotherapy is equally effective andless toxic compared with extended-field radiotherapy after fourcycles of chemotherapy in patients with early-stage unfavorableHodgkin's lymphoma:results of the HD8 trial of theGerman Hodgkin's Lymphoma Study Group" 21 : 3601-8, 2003

15 "Hodgkin's lymphoma: biology and treatment strategies forprimary, refractory, and relapsed disease." 225-47, 2003

16 "Consolidation radiation after complete remission inHodgkin's disease following six cycles of doxorubicin, bleomycin,vinblastine, and dacarbazine chemotherapy: is there aneed?" 22 : 62-8, 2004

17 "Combination chemotherapyin the treatment of advanced Hodgkin's disease" 73 : 881-95, 1970

18 "Combination chemotherapy of Hodgkin's disease withadriamycin" 252-9, 1975

19 "Clinical observationon 55 cases of Hodgkin's disease" 17 : 35-44, 1982

20 "Chemotherapy alone compared with chemotherapyplus radiotherapy for localized intermediate- and highgradenon-Hodgkin's lymphoma" 339 : 21-6, 1998

21 "British national lymphomainvestigation randomised study of MOPP Leukeransubstituted for mustine" 579-82, 1991

22 "10-year experience withAVBD plus radiotherapy; subtotal nodal (STNI) versus involvedfield(IFRT) in early-stage Hodgkin's disease." 20 : 281-, 2001